Potential targeted therapy options in the management of basal cell subtype of breast carcinoma.
Harputluoglu
Hakan
H
Dizdar
Omer
O
Altundag
Kadri
K
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051929:CD146 Antigen / Q000378:metabolism; D051242:Caveolin 1 / Q000378:metabolism; D017326:Clinical Trials, Phase III as Topic; D000069439:Dasatinib; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D018295:Neoplasms, Basal Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017239:Paclitaxel / Q000627:therapeutic use; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000970:Antineoplastic Agents; C495540:CAV1 protein, human; D051929:CD146 Antigen; D051242:Caveolin 1; D011743:Pyrimidines; D013844:Thiazoles; D019859:Proto-Oncogene Proteins c-met; D017239:Paclitaxel; D000069439:Dasatinib